Background: Patients with liver cirrhosis, due to immunological dysfunction, are at a significant risk for getting SARS-Cov-2 infection, which accounts for 1.2 million deaths annually around the world. Objective: To study impact of COVID-19 on morbidity and mortality among patients with compensated cirrhosis. Patients and Methods: Our prospective cohort study was done at Ahmed Maher Teaching Hospital, and Internal Medicine Department of Zagazig University Hospitals, this study was performed on 180 patients. The included patients are classified into two groups; ninety COVID-19-infected patients with chronic liver disease (CLD) and ninety non-CLD patients with COVID. PCR, liver functions as well as pelvi-abdominal Ultrasound were done to all patients. Results: There is statistically significant difference between both groups regarding mortality. About 18% and 7% within CLD with COVID and non-CLD with COVID groups respectively died by the end. There is statistically significant relation between mortality among CLD patients with COVID and CRP and ESR levels (both were significantly lower among survivors). There is statistically significant relation between hepatic encephalopathy among CLD patients with COVID and ESR levels (both were significantly lower among those with hepatic encephalopathy). Conclusion: Both preexisting medical issues and those that arise during hospitalisation appear to have a significant impact on the mortality of COVID-19 patients. Hospitalized cirrhotic individuals whose survival rates have been studied for the impact of SARS-CoV-2 infection can provide further additional details.